Time reveals the truth.pdf

0 likes29 views

The document discusses the effectiveness of low-dose radiation therapy (LDRT) compared to antiviral treatments for COVID-19, emphasizing the risks of antiviral resistance due to selective pressure on the virus mutations. Studies suggest that while antiviral drugs can lead to treatment-resistant variants, LDRT has shown promise in improving clinical outcomes without acute toxicity. The paper highlights the ongoing debate about the acceptance of LDRT as a viable treatment option amid the prevailing preference for antiviral drugs.

Health & Medicine

Time reveals the
truth!
Antivirals Vs. LDRT
Low-Dose Radiation Therapy for COVID-19

SMJ Mortazavi, Ph.D
5
29 June 2022
“Taken together, the studies show that
“when you put pressure on the virus it
escapes,” says David Ho, a virologist at
Columbia University”
“That rise creates selective pressure on
the virus, favoring mutations that help it
survive in the presence of the drug. And
because each infected person makes
trillions of copies of SARS-CoV-2, the virus
has plenty of opportunities to test out
different mutations as it replicates”.
https://www.science.org/content/article/bad-news-paxlovid-
coronavirus-can-find-multiple-ways-evade-covid-19-drug

SMJ Mortazavi, Ph.D
6
“In less than a month, the report by Ghadimi-Moghadam et
al.4 received attention not only for introducing LDRT as a
treatment method for pneumonia in COVID-19 patients but
also for noting the key disadvantages of other treatment
methods such as using antiviral drugs. Rödel et al.5 in their
paper published recently state SARS-COV-2 is an RNA virus
with an expected moderate to high mutation rate …..6 In
addition, as discussed in a recent manuscript,4 any antiviral
drug treatment against SARS-CoV-2 would probably result in
a more intense selective pressure on the virus. Moreover
Dilucca et al.7 in their paper published recently in the
Viruses Journal highlight the importance of LDRT and
address the potential problems associated with the
widespread use of different antiviral drugs as discussed in a
recent paper,4 any antiviral drug against SARS-CoV-2 would
exert an intense selective pressure on the virus.This may
result in highly adaptive and treatment-resistant virus types
with enhanced pathogenicity”.
Rebuttal:
SMJ Mortazavi, Ph.D
Point/Counterpoint
Low-dose radiation as a treatment for
COVID-19 pneumonia: A threat or real
opportunity?
Seyed Mohammad Javad Mortazavi
Ph.D.,Amirhosein Kefayat M.D.,Jing Cai
Ph.D.
First published: 03 July 2020
https://doi.org/10.1002/mp.14367
2 years ago (July 2020)

SMJ Mortazavi, Ph.D
7
Low-Dose Radiation Therapy for COVID-19
Time reveals the truth!

Part 2
Which treatment is
buried, Antivirals or
LDRT?

SMJ Mortazavi, Ph.D
9
“It is somehow apparent that
using antiviral drugs and
vaccines for COVID-19
treatment would be more
acceptable for patients in
comparison with ionizing
radiations even in low-dose
form.Therefore, further
achievements in these fields
like approving Remdesivir for
COVID-19 treatment25 may
bury the subject of
employing LDRT for COVID-19
treatment“.
Rebuttal:
Amirhosein Kefayat, M.D
Point/Counterpoint
Low-dose radiation as a treatment for COVID-
19 pneumonia: A threat or real opportunity?
Seyed Mohammad Javad Mortazavi
Ph.D.,Amirhosein Kefayat M.D.,Jing Cai Ph.D.
First published: 03 July 2020
https://doi.org/10.1002/mp.14367
2 years ago (July 2020)

SMJ Mortazavi, Ph.D
10
“. ……any antiviral drug
against SARS-CoV-2 would
exert an intense selective
pressure on the virus.This
may result in highly
adaptive and treatment-
resistant virus types with
enhanced pathogenicity.”.
Rebuttal:
SMJ Mortazavi, Ph.D
Point/Counterpoint
Low-dose radiation as a treatment for COVID-
19 pneumonia: A threat or real opportunity?
Seyed Mohammad Javad Mortazavi
Ph.D.,Amirhosein Kefayat M.D.,Jing Cai Ph.D.
First published: 03 July 2020
https://doi.org/10.1002/mp.14367
2 years ago (July 2020)

▪WHO Guideline
Development Group
advises against use
of remdesivir for
covid-19.
Rodríguez-Tomàs et al. Antioxidants 2022,
11(6), 1184;
https://doi.org/10.3390/antiox11061184,
Published: 16 June 2022
11
Time reveals the truth!
Now, after 2 years, we know that:
 Several groups, including our own,
have shown that whole-lung
radiation at doses of 0.5–1.5 Gy can
accelerate the recovery in clinical
and radiographic status without
acute toxicity
[12,13,14,15,16,17,18,19,20,21].".
LDRT for COVID-19

And viruses can evolve faster when there is
selection pressure, he says, because mutations
are more likely to stick around if they give the
virus an increased ability to propagate under
certain environmental conditions.

The document discusses the implications of antiviral drugs and low-dose radiation therapy (LDRT) in treating COVID-19, highlighting that antiviral treatments may create selective pressure on the virus, leading to mutations and resistance. Studies have suggested LDRT as a feasible and safe alternative that may aid recovery in severe cases of COVID-19 pneumonia without significant toxicity. Further clinical trials are recommended to evaluate the effectiveness of LDRT in this context.

How did we trigger scientists around the globe to uncover the low dose radiat...SMJ Mortazavi

��

The document discusses the exploration of low dose radiation therapy (LDRT) as a potential treatment for COVID-19, highlighting that it does not exert selective pressure on the virus, unlike antiviral drugs. LDRT aims to manage pneumonia symptoms and complications, showing promise in improving patient recovery times and immune responses. It emphasizes the importance of further research and clinical trials to validate these findings and suggest combining LDRT with other therapies, like convalescent plasma, for enhanced therapeutic effects.

Low Dose Radiation Therapy (LDRT) for COVID-19 PneumoniaMatthew Katz

��

The document discusses low dose radiation therapy (LDRT) as a treatment for COVID-19 pneumonia, highlighting its historical use, clinical trials, and evolving perspectives on its safety and efficacy. It addresses the collaboration of experts and the implementation of trials to evaluate LDRT's effectiveness in reducing severe outcomes in high-risk COVID-19 patients. The ongoing trials aim to determine optimal radiation doses and assess potential benefits against risks related to treatment.

Coronavirus disease 2019LORENZONEITA

��

This document reviews potential treatment options for COVID-19 that are supported by early evidence. It summarizes in vitro and clinical evidence for remdesivir, chloroquine/hydroxychloroquine, and lopinavir/ritonavir. Remdesivir shows potent activity against SARS-CoV-2 and other coronaviruses in vitro and clinical benefit in animal studies of MERS and Ebola. Early clinical data in COVID-19 patients treated with remdesivir showed improvement. Chloroquine also has in vitro activity against SARS-CoV-2 and is supported by some clinical case studies from China. However, the efficacy of these agents specifically for COVID-19 treatment requires further evaluation in controlled

02_IJPBA_1948_21_Revised.pdfBRNSS Publication Hub

��

This document discusses the status of various antiviral agents for treating COVID-19. It describes drugs such as lopinavir-ritonavir, favipiravir, and remdesivir, which have been tested for treating COVID-19. Clinical trials have shown that lopinavir-ritonavir does not provide benefits beyond standard care. Favipiravir may help reduce viral shedding time but results are mixed. Remdesivir received FDA approval for treating COVID-19 based on preliminary studies showing improved outcomes, but the WHO recommends against its use due to insufficient evidence. Newer antiviral drugs are still undergoing clinical trials to determine their efficacy for COVID-19 treatment.

02_IJPBA_1948_21_Revised.pdfBRNSS Publication Hub

��

This document discusses the status of various antiviral agents for treating COVID-19, including lopinavir-ritonavir, favipiravir, and remdesivir. Lopinavir-ritonavir clinical trials did not show benefits for COVID-19 treatment. Favipiravir results were mixed, with some studies showing faster viral clearance but no benefit in others. Remdesivir received FDA approval for COVID-19 treatment based on clinical trials showing faster recovery, but the WHO conditionally recommends against its use due to insufficient evidence of improved survival. Many potential COVID-19 treatments remain under clinical investigation.

COVID-19 – A Lung Doc's PerspectiveM. Patricia George

��

This document provides a lung doctor's perspective on COVID-19. It summarizes that COVID-19 is caused by a coronavirus called SARS-CoV-2. It transmits through respiratory droplets and contaminated surfaces. Common symptoms include pneumonia and acute respiratory distress syndrome. Older individuals and those with preexisting conditions are at higher risk. Treatments include remdesivir, dexamethasone, and convalescent plasma depending on severity of illness. Chronic manifestations are still unknown. The doctor discusses their experience treating COVID-19 cases in Colorado and anticipation of a potential second wave in the fall.

Hawaii - American Medical Association - Advancing Science - Ethics and Profes...Clifton M. Hasegawa & Associates, LLC

��

The document outlines several key points regarding COVID-19 vaccines and treatments, asserting that there is no vaccine providing immunization against the SARS-CoV-2 coronavirus and describing the COVID-19 vaccine as an experimental therapeutic drug. It discusses the controversial use of hydroxychloroquine and ivermectin, with no consensus on their efficacy for treating COVID-19, while emphasizing the importance of evidence-based medicine in prescribing practices. Additionally, it highlights the need for effective therapeutics, such as monoclonal antibodies and remdesivir, and the challenges associated with their usage in treating COVID-19 patients.

covid-9 clinical_management_and_treatment.pptxsergeipee

��

This document discusses clinical management and treatment approaches for COVID-19. It recommends supportive care for most patients, with hospitalization only for those with more severe symptoms. Several investigational antiviral drugs and host-targeting approaches are mentioned as having in vitro activity against COVID-19 and being studied clinically. These include remdesivir, lopinavir/ritonavir, favipiravir, and chloroquine. Immunomodulators like tocilizumab are also under investigation to control excessive immune response in severe cases. Overall, no specific treatment has proven efficacy against COVID-19 yet, and management focuses on supportive care while clinical trials evaluate potential therapies.

To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...YogeshIJTSRD

��

This study assesses the severity and mortality among COVID-19 patients in relation to their vaccination status. Out of 100 participants, it was found that 76% of the mortality cases involved non-vaccinated individuals, while vaccinated individuals had a significantly lower mortality rate. The findings suggest that vaccination leads to reduced infection rates and lower mortality in COVID-19 patients.

remdesivir pro.pptxHardikVekariya17

��

The document discusses the role of remdesivir in treating COVID-19. It provides background on remdesivir, describing it as an antiviral drug originally developed to treat Ebola. Studies have shown it inhibits SARS-CoV-2 replication and is effective against the virus. Several clinical trials on COVID-19 patients, including a NIH trial, found remdesivir reduced recovery time. However, limitations include small sample sizes and lack of control groups. While promising, more research is still needed to confirm remdesivir's efficacy against COVID-19.

Coronavirus ppt converted (3) pdf3Vinod Kurmi

��

1) The document summarizes the present status of the COVID-19 pandemic, including epidemiology showing over 100,000 cases worldwide and transmission primarily occurring via contact with infected surfaces or people. 2) Clinical management includes home care for mild cases with monitoring, hospitalization for severe cases, supportive care, collection of specimens from the upper and lower respiratory tract for testing, and treatment of hypoxemic respiratory failure. 3) Experimental treatments discussed include the antiviral drugs lopinavir/ritonavir, remdesivir, and chloroquine, as well as traditional Chinese medicines, though effective treatments have not yet been verified. Prevention is emphasized as the best approach currently.

Remdesivir in the Management of COVID-19: Evidence Based Approachfarah al souheil

��

The document discusses the evidence-based approach to using Remdesivir in the treatment of COVID-19, outlining its mechanism of action, clinical efficacy, and approval status as of June 2020. It summarizes the virus's transmission, clinical presentations, treatment protocols, and various clinical trials that evaluate Remdesivir's impact on patients. The document also highlights the promising results from trials that indicate Remdesivir can shorten recovery times, while noting complications and adverse events associated with its use.

Management of COVID -19.pptxJindal Chest Clinic

��

1. The document discusses the management of COVID-19, including its pathophysiology involving cytokine storms, diagnostic criteria, treatments such as remdesivir, steroids, IL-6 blockade, and atypical complications like COVID-associated pulmonary aspergillosis. 2. Radiology plays a role in diagnosis but should not be used for routine screening or as a substitute for clinical severity. Treatments are tailored based on disease severity from mild to severe. 3. The key is focusing on clinical monitoring over tests, treating the underlying hyperinflammation, and reassuring patients and society about COVID-19 being treated like other infections.

Low-dose radiation therapy (LDRT) for COVID-19 associated pneumoniaSMJ Mortazavi

��

The document discusses low-dose radiation therapy (LDRT) for treating COVID-19 associated pneumonia. It notes that LDRT may help manage pneumonia symptoms by reducing inflammation through anti-inflammatory effects. Doses up to 250 mGy are proposed, which is lower than doses from some medical imaging procedures. LDRT is not expected to exert significant selective pressure on the virus due to its very low dose. Rather than trying to inactivate the virus, LDRT aims to optimize immune function against infection and better manage pneumonia complications.

Coronavirus Pandemic Part III (B): Therapeutic OptionsKumaraguru Veerasamy

��

The document provides a comprehensive overview of potential therapeutic options and treatment pathways for COVID-19, emphasizing the urgency for effective diagnostics, treatments, and vaccines amidst the pandemic. It discusses various mechanisms of action of antiviral therapeutics, monoclonal antibodies, and convalescent plasma, while highlighting several promising candidates like remdesivir and avigan. The document also outlines ongoing research and development efforts to address critical healthcare needs related to COVID-19 treatment.

Cs e book 2 - dr. mccullough’s proven covid treatmentsssuser1fa8cb

��

This document discusses Dr. Peter McCullough's views on treating COVID-19, the Omicron variant, and vaccines. It summarizes an interview where Dr. McCullough explains that Omicron is less severe than Delta, spreads faster, and may provide natural immunity. He questions the need to mass vaccinate for a mild illness and says vaccines may not be effective against Omicron based on early data. The document advocates for early treatment of high-risk COVID patients to reduce mortality.

COVID-19 vaccines in cancer patients Dr. Nabil El-HadiNabil El-Hady

��

This document provides information about COVID-19 vaccination in cancer patients by answering common questions. It discusses that cancer patients are eligible for COVID-19 vaccines as long as they have no contraindications. While vaccines have not been tested in cancer patients, post-authorization studies are planned. The document recommends vaccination timing and managing expected side effects. It also reviews guidelines on vaccination for different cancer types and treatments.

Remdesivir ; Role of remdesivir in COVID 19Shikha Panwar

��

Remdesivir is an antiviral drug originally developed to treat Ebola. Studies show it inhibits the replication of SARS-CoV-2 by interfering with the virus's RNA polymerase. Early trials of remdesivir for COVID-19 showed improvement in most patients, but were limited by small sample sizes and lack of controls. A larger controlled trial in China found no significant difference in time to clinical improvement between remdesivir and placebo. An ongoing NIH trial shows remdesivir may reduce recovery time compared to placebo, with potential for reduced mortality, but is still preliminary with only interim analyses of 1000 patients so far.

Ιωάννης Κατσαρόλης, Health Innovation Conference 2021Starttech Ventures

��

Remdesivir is an antiviral medication approved for treating COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen. It was granted conditional marketing authorization due to its ability to address an unmet medical need, despite having less comprehensive data than typically required. Clinical trials have shown that remdesivir accelerates recovery and reduces mortality rates in patients with low-flow oxygen requirements.

Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical G...PVI, PeerView Institute for Medical Education

��

The document outlines the severity spectrum of COVID-19, categorizing cases from asymptomatic infections to critical illness. It provides clinical tips for healthcare providers, treatment guidelines for hospitalized patients, and discusses potential antiviral drugs and immune-based therapies under evaluation. Key recommendations include the use of remdesivir for severe cases and caution against hydroxychloroquine and certain immunomodulators, emphasizing the need for ongoing clinical trials.

Ms cs for_critically_ill_covid-19_patients.pdfComprehensiveBiologi

��

This document discusses the COVID-19 pandemic and potential treatments for the disease. It notes that COVID-19 has led to a national emergency in the US with significant health and economic impacts. Currently, there is no cure for COVID-19 and the disease spectrum varies from asymptomatic to severe cases requiring ICU care. The document explores the pathogenesis of the virus and notes that a "cytokine storm" may be a key driver of organ damage. It reviews several potential treatments under investigation including vaccines, antiviral medications, and stem cell therapies. It highlights reports from China and Italy using expanded umbilical cord mesenchymal stem cells (UC-MSCs) to treat COVID-19 and argues they may be considered for compassionate

Covid19 corona management -كوفيد19MEEQAT HOSPITAL

��

The document outlines critical treatment protocols for COVID-19, emphasizing the prompt initiation of antivirals, antibiotics, and corticosteroids upon radiological findings. It discusses the roles of various medications like tocilizumab, diuretics, and anticoagulants, highlighting their importance in improving patient outcomes and preventing complications. The psychological state of the patient is also noted as a significant factor affecting treatment success.

Journal Club Evaluation (COVID-19).pptxzeinabnm

��

The document discusses a study comparing the time to clinical improvement in hospitalized COVID-19 patients treated with remdesivir versus those who were not. The study highlights the pathophysiology, epidemiology, and treatment modalities for COVID-19, revealing that remdesivir significantly shortens the time to recovery. Additionally, it details a multicenter retrospective analysis of patient outcomes, linking remdesivir use with improved recovery times.

Paxlovid and Molnupiravir What Are The Differences.pdfDoriaFang

��

This document discusses the differences in efficacy and mechanisms of action between two oral COVID-19 antiviral drugs: molnupiravir (Lagevrio) and paxlovid. Clinical trials indicate that paxlovid significantly outperforms molnupiravir in reducing the risk of hospitalization and death among high-risk patients. The document also explores the drug development mechanisms and public health implications of these treatments in the context of COVID-19.

CoronavirusFlavio Pereira

��

This document summarizes two reviews on the use of chloroquine and hydroxychloroquine to treat COVID-19. The first review identified 9 studies including 3 clinical trials of 150 patients that suggested chloroquine and hydroxychloroquine can successfully treat COVID-19. It also found COVID-19 is less common in areas where malaria is more common. The second review discussed ongoing clinical trials of various potential drugs and therapeutic approaches to treat and prevent COVID-19, including remdesivir, favipiravir, lopinavir/ritonavir, chloroquine, hydroxychloroquine and corticosteroids, though definitive results are still pending.

Covid 19 therapeuticsAMITH SREEDHARAN

��

Favipiravir is an antiviral drug being studied for the treatment of COVID-19. The document summarizes several studies on favipiravir including: a randomized controlled trial from China finding favipiravir led to faster viral clearance and improved chest imaging outcomes compared to lopinavir/ritonavir; observational data from Japan showing clinical improvement in most patients, especially those with mild/moderate disease; and a Russian study demonstrating improved viral clearance and fever relief with favipiravir versus standard of care. The document also reviews favipiravir's mechanism of action, potential adverse effects, and prescribing guidelines.

COVID-19 Therapeutics Update (End Q1 2021)Kumaraguru Veerasamy

��

As of April 2021, the fight against COVID-19 continues with over 18 million active cases globally, with approved therapies including Gilead's antiviral remdesivir and various monoclonal antibodies. Dexamethasone, a corticosteroid, has shown effectiveness in reducing deaths among critically ill patients, while supportive therapies like ventilators and prone positioning remain crucial. Despite advances in treatments, healthcare systems face ongoing challenges due to the high number of patients requiring care.

Mercury Released from Dental Amalgam Fillings in Response to Different Physic...SMJ Mortazavi

��

A systematic review indicates that various physical stressors, including electromagnetic fields and radiation, significantly increase mercury release from dental amalgam fillings, posing risks particularly to vulnerable populations such as children and pregnant women. The study aligns with FDA warnings regarding dental amalgam safety for these high-risk groups. Researchers emphasize the need for further exploration into genetic susceptibility to mercury toxicity and the implications of electromagnetic exposure on health.

Final-How Some INIRPRC’s Studies Can Re-Route the Direction of Global Science...SMJ Mortazavi

��

The document discusses the significant contributions of INIRPRC's research in the context of global science, emphasizing studies on cosmic radiation and protective measures for long-term space missions. It highlights innovations in radiation shielding materials and explores the role of low-dose radiation in COVID-19 treatment, presenting it as a potential game changer in medical science. The findings suggest rehabilitation from high radiation exposure and improvements in astronaut protection through adaptive biological responses and advanced shielding techniques.

More Related Content

Similar to Time reveals the truth.pdf (20)

covid-9 clinical_management_and_treatment.pptxsergeipee

��

To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...YogeshIJTSRD

��

remdesivir pro.pptxHardikVekariya17

��

Coronavirus ppt converted (3) pdf3Vinod Kurmi

��

Remdesivir in the Management of COVID-19: Evidence Based Approachfarah al souheil

��

Management of COVID -19.pptxJindal Chest Clinic

��

Low-dose radiation therapy (LDRT) for COVID-19 associated pneumoniaSMJ Mortazavi

��

Coronavirus Pandemic Part III (B): Therapeutic OptionsKumaraguru Veerasamy

��

Cs e book 2 - dr. mccullough’s proven covid treatmentsssuser1fa8cb

��

COVID-19 vaccines in cancer patients Dr. Nabil El-HadiNabil El-Hady

��

Remdesivir ; Role of remdesivir in COVID 19Shikha Panwar

��

Ιωάννης Κατσαρόλης, Health Innovation Conference 2021Starttech Ventures

��

Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical G...PVI, PeerView Institute for Medical Education

��

Ms cs for_critically_ill_covid-19_patients.pdfComprehensiveBiologi

��

Covid19 corona management -كوفيد19MEEQAT HOSPITAL

��

Journal Club Evaluation (COVID-19).pptxzeinabnm

��

Paxlovid and Molnupiravir What Are The Differences.pdfDoriaFang

��

CoronavirusFlavio Pereira

��

Covid 19 therapeuticsAMITH SREEDHARAN

��

COVID-19 Therapeutics Update (End Q1 2021)Kumaraguru Veerasamy

��

covid-9 clinical_management_and_treatment.pptxsergeipee

��

To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...YogeshIJTSRD

��

remdesivir pro.pptxHardikVekariya17

��

Coronavirus ppt converted (3) pdf3Vinod Kurmi

��

Remdesivir in the Management of COVID-19: Evidence Based Approachfarah al souheil

��

Management of COVID -19.pptxJindal Chest Clinic

��

Low-dose radiation therapy (LDRT) for COVID-19 associated pneumoniaSMJ Mortazavi

��

Coronavirus Pandemic Part III (B): Therapeutic OptionsKumaraguru Veerasamy

��

Cs e book 2 - dr. mccullough’s proven covid treatmentsssuser1fa8cb

��

COVID-19 vaccines in cancer patients Dr. Nabil El-HadiNabil El-Hady

��

Remdesivir ; Role of remdesivir in COVID 19Shikha Panwar

��

Ιωάννης Κατσαρόλης, Health Innovation Conference 2021Starttech Ventures

��

Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical G...PVI, PeerView Institute for Medical Education

��

Ms cs for_critically_ill_covid-19_patients.pdfComprehensiveBiologi

��

Covid19 corona management -كوفيد19MEEQAT HOSPITAL

��

Journal Club Evaluation (COVID-19).pptxzeinabnm

��

Paxlovid and Molnupiravir What Are The Differences.pdfDoriaFang

��

CoronavirusFlavio Pereira

��

Covid 19 therapeuticsAMITH SREEDHARAN

��

COVID-19 Therapeutics Update (End Q1 2021)Kumaraguru Veerasamy

��

More from SMJ Mortazavi (8)

Mercury Released from Dental Amalgam Fillings in Response to Different Physic...SMJ Mortazavi

��

Final-How Some INIRPRC’s Studies Can Re-Route the Direction of Global Science...SMJ Mortazavi

��

How Crucial is the Importance of COVID-19 in Long-Term Space Missions?SMJ Mortazavi

��

The document discusses the significance of COVID-19 in the context of long-term space missions, emphasizing challenges such as space radiation, microgravity, and immune system dysregulation. It highlights concerns around long COVID-19 and the emergence of new SARS-CoV-2 variants with increased pathogenicity and transmissibility. The authors, affiliated with various institutions, underscore the importance of addressing these health risks in space exploration.

Why it is of paramount importance to know the source of funding in emf resear...SMJ Mortazavi

��

The talk emphasizes the critical importance of understanding funding sources in electromagnetic field (EMF) research, particularly in relation to 5G technology. It discusses health risks associated with RF-EMF exposure, potential biases from the telecom industry, and highlights concerning studies that downplay the risks of mobile phone use. The presentation calls for more rigorous research to ensure accurate assessments of health risks related to EMF exposure, especially for vulnerable populations like children.

The Challenges of J-shaped Dose Response Models for Ionizing and Non-ionizing...SMJ Mortazavi

��

The document discusses the complexities of J-shaped dose-response models for both ionizing and non-ionizing radiation, highlighting controversies in the application of these models to health risks. It critiques the linear no-threshold (LNT) model, suggesting that emerging evidence does not support it as a reliable method for radiation risk assessment. The author emphasizes the potential health risks of technologies such as 5G and the need for further investigation into the biological effects of radiofrequency exposure.

Lecture at University of Wisconsin, Madison - April 2, 2018SMJ Mortazavi

��

The document discusses the concept of adaptive response as a potential method to reduce the risks of acute radiation syndrome and infections during long-term space missions, particularly to Mars. It emphasizes the importance of selecting astronauts based on their individual adaptive responses to radiation, supported by various studies and NASA reports. The integrative protection plan proposed includes physical shielding, biological protection methods, and the significance of understanding radiation-induced responses in long-duration missions.

Strategies for reducing the risk of radiation for astronauts in space mission...SMJ Mortazavi

��

The document outlines strategies for reducing radiation risk for astronauts during space missions, particularly to Mars, emphasizing the limitations of physical shielding in space and the potential of adaptive biological responses. It details experimental approaches to understanding these responses and the importance of selecting astronauts based on their individual radioadaptive capabilities. The integration of physical shielding and biological protection methods, including radiation mitigators, is proposed as a comprehensive protection plan against both galactic cosmic radiation and solar particle events.

How does biological protection help astronauts tolerate high levels of radiationSMJ Mortazavi

��

The document discusses the challenges of protecting astronauts from high levels of radiation during deep space missions, emphasizing the inadequacy of physical shielding. It proposes an integrative radiation protection plan that includes adaptive response and biological protection methods, highlighting the significance of selecting astronauts with a high magnitude of adaptive response. Additionally, it introduces vitamin C as a potential radiomitigator that can enhance survival rates after radiation exposure.

Mercury Released from Dental Amalgam Fillings in Response to Different Physic...SMJ Mortazavi

��

Final-How Some INIRPRC’s Studies Can Re-Route the Direction of Global Science...SMJ Mortazavi

��

How Crucial is the Importance of COVID-19 in Long-Term Space Missions?SMJ Mortazavi

��

Why it is of paramount importance to know the source of funding in emf resear...SMJ Mortazavi

��

The Challenges of J-shaped Dose Response Models for Ionizing and Non-ionizing...SMJ Mortazavi

��

Lecture at University of Wisconsin, Madison - April 2, 2018SMJ Mortazavi

��

Strategies for reducing the risk of radiation for astronauts in space mission...SMJ Mortazavi

��

How does biological protection help astronauts tolerate high levels of radiationSMJ Mortazavi

��

Recently uploaded (20)

Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on...PVI, PeerView Institute for Medical Education

��

Co-Chairs, Prof. Dr. Patrick Schöffski, MPH, and Breelyn A. Wilky, MD, discuss desmoid tumors in this CME activity titled “Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/4iDPUQY. CME credit will be available until June 29, 2026.

From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With...PVI, PeerView Institute for Medical Education

��

Irradiation to prevent TA-GvHD by Dr. Abrar Kabir Shishir.pptxAbrarKabir3

��

Mastering the Review Article: Structure, Strategy & SuccessRajendra Dev Bhatt

��

nanoparticle and liposomes ppt .(NTDS)pdfsiddhikalbande

��

Abdominal Radiology - x-rays of abdomenRahul Kadam

��

Quality by Design Tools in Pharmaceutical Manufacturing Technology39KomalZaveri

��

Yoga Postures to Practicefor Holistic (Physical, Mental, and Cognitive) Well...Bhoj Raj Singh

��

An ancient System for holistic health (mental and physical) and wellbeing, is a scientific art of living with harmony (connecting) of mind and body. Although much more ancient than Patanjali, who documented yoga systematically about 2000 years ago, Patanjali is often referred to as the "father of modern yoga." Yoga postures are commonly depicted in ancient paintings, carvings, and sculptures in almost all civilizations and religions, thus Yoga can’t be described as an act of Hinduism. It originated long before any religion on Earth, with the emergence of life on the Planet. All yoga poses are natural, and what is not natural is not yoga; it is��Viyoga. Besides Vedic Yoga, Hatha, Vinyasa, Ashtanga, Iyengar, Yin, Restorative, Kundalini, Bikram, Sahaj, and Power yoga are some popular types. Vinyasa��Yoga is the closest form to Vedic Yoga; it is known for its flowing movements, not very rigorous, not too much straining, actions flow with the breath. Though all yoga may lead to meditation (Dhyan) for your inner upliftment, it is not the same as described in Hinduism for self-liberation. In Hinduism, different paths of life looking distinct but can be practiced all together, they are: Karma Yoga (selfless action and service), Bhakti Yoga (devotion and love for God or Godly power), Jnana (Gyan) Yoga (gaining knowledge for self-realization through wisdom), Dhyan Yoga (meditation) and Kriya Yoga (optimum utilization of your vital and muscular energy).��

Protein Biochemistry (1).pptx by Professor I.H MAINAlegendnasir83

��

INTERPRETATION OF LABORATORY INVESTIGATIONS.pptxEliLawluvi

��

Tuberculosis Nepal 2025 National Plan.pptxDr. Anu Marhatta

��

OUR SRS SBRT EXPERIENCE BY DR KANHU CHARAN PATROKanhu Charan

��

the list of FABELS in neonatology (1).pptxDrSandeepDankhade

��

Bias, Cofounding Bias, Matching , BlindingDr. Anu Marhatta

��

Update on Anesthesia for Pediatric Ophthalmic Surgery.pptxDr.Umang Sharma

��

Day care surgery anaesthesia and management of complications in postoperative...deepika582423

��

Severe Acute Respiratory Syndrome (SARS)Dr. Anu Marhatta

��

Coarse Dispersion, Physical Pharmaceuticsnishiprakashj

��

Tooth paste - BDS.docxkopalsharma85

��

Computer aided formulation development optimizationSwami ramanand teerth marathwada university

��

Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on...PVI, PeerView Institute for Medical Education

��

From Wheals to Wellness: Transforming Chronic Spontaneous Urticaria Care With...PVI, PeerView Institute for Medical Education

��

Irradiation to prevent TA-GvHD by Dr. Abrar Kabir Shishir.pptxAbrarKabir3

��

Mastering the Review Article: Structure, Strategy & SuccessRajendra Dev Bhatt

��

nanoparticle and liposomes ppt .(NTDS)pdfsiddhikalbande

��

Abdominal Radiology - x-rays of abdomenRahul Kadam

��

Quality by Design Tools in Pharmaceutical Manufacturing Technology39KomalZaveri

��

Yoga Postures to Practicefor Holistic (Physical, Mental, and Cognitive) Well...Bhoj Raj Singh

��

Protein Biochemistry (1).pptx by Professor I.H MAINAlegendnasir83

��

INTERPRETATION OF LABORATORY INVESTIGATIONS.pptxEliLawluvi

��

Tuberculosis Nepal 2025 National Plan.pptxDr. Anu Marhatta

��

OUR SRS SBRT EXPERIENCE BY DR KANHU CHARAN PATROKanhu Charan

��

the list of FABELS in neonatology (1).pptxDrSandeepDankhade

��

Bias, Cofounding Bias, Matching , BlindingDr. Anu Marhatta

��

Update on Anesthesia for Pediatric Ophthalmic Surgery.pptxDr.Umang Sharma

��

Day care surgery anaesthesia and management of complications in postoperative...deepika582423

��

Severe Acute Respiratory Syndrome (SARS)Dr. Anu Marhatta

��

Coarse Dispersion, Physical Pharmaceuticsnishiprakashj

��

Tooth paste - BDS.docxkopalsharma85

��

Computer aided formulation development optimizationSwami ramanand teerth marathwada university

��

Time reveals the truth.pdf

1. Time reveals the truth! Antivirals Vs. LDRT Low-Dose Radiation Therapy for COVID-19

2. Part 1 Dark Side of Antivirals

3. SMJ Mortazavi, Ph.D 3 Dec 22, 2021

4. SMJ Mortazavi, Ph.D 4 29 June 2022

5. SMJ Mortazavi, Ph.D 5 29 June 2022 “Taken together, the studies show that “when you put pressure on the virus it escapes,” says David Ho, a virologist at Columbia University” “That rise creates selective pressure on the virus, favoring mutations that help it survive in the presence of the drug. And because each infected person makes trillions of copies of SARS-CoV-2, the virus has plenty of opportunities to test out different mutations as it replicates”. https://www.science.org/content/article/bad-news-paxlovid- coronavirus-can-find-multiple-ways-evade-covid-19-drug

6. SMJ Mortazavi, Ph.D 6 “In less than a month, the report by Ghadimi-Moghadam et al.4 received attention not only for introducing LDRT as a treatment method for pneumonia in COVID-19 patients but also for noting the key disadvantages of other treatment methods such as using antiviral drugs. Rödel et al.5 in their paper published recently state SARS-COV-2 is an RNA virus with an expected moderate to high mutation rate …..6 In addition, as discussed in a recent manuscript,4 any antiviral drug treatment against SARS-CoV-2 would probably result in a more intense selective pressure on the virus. Moreover Dilucca et al.7 in their paper published recently in the Viruses Journal highlight the importance of LDRT and address the potential problems associated with the widespread use of different antiviral drugs as discussed in a recent paper,4 any antiviral drug against SARS-CoV-2 would exert an intense selective pressure on the virus.This may result in highly adaptive and treatment-resistant virus types with enhanced pathogenicity”. Rebuttal: SMJ Mortazavi, Ph.D Point/Counterpoint Low-dose radiation as a treatment for COVID-19 pneumonia: A threat or real opportunity? Seyed Mohammad Javad Mortazavi Ph.D.,Amirhosein Kefayat M.D.,Jing Cai Ph.D. First published: 03 July 2020 https://doi.org/10.1002/mp.14367 2 years ago (July 2020)

7. SMJ Mortazavi, Ph.D 7 Low-Dose Radiation Therapy for COVID-19 Time reveals the truth!

8. Part 2 Which treatment is buried, Antivirals or LDRT?

9. SMJ Mortazavi, Ph.D 9 “It is somehow apparent that using antiviral drugs and vaccines for COVID-19 treatment would be more acceptable for patients in comparison with ionizing radiations even in low-dose form.Therefore, further achievements in these fields like approving Remdesivir for COVID-19 treatment25 may bury the subject of employing LDRT for COVID-19 treatment“. Rebuttal: Amirhosein Kefayat, M.D Point/Counterpoint Low-dose radiation as a treatment for COVID- 19 pneumonia: A threat or real opportunity? Seyed Mohammad Javad Mortazavi Ph.D.,Amirhosein Kefayat M.D.,Jing Cai Ph.D. First published: 03 July 2020 https://doi.org/10.1002/mp.14367 2 years ago (July 2020)

10. SMJ Mortazavi, Ph.D 10 “. ……any antiviral drug against SARS-CoV-2 would exert an intense selective pressure on the virus.This may result in highly adaptive and treatment- resistant virus types with enhanced pathogenicity.”. Rebuttal: SMJ Mortazavi, Ph.D Point/Counterpoint Low-dose radiation as a treatment for COVID- 19 pneumonia: A threat or real opportunity? Seyed Mohammad Javad Mortazavi Ph.D.,Amirhosein Kefayat M.D.,Jing Cai Ph.D. First published: 03 July 2020 https://doi.org/10.1002/mp.14367 2 years ago (July 2020)

11. ▪WHO Guideline Development Group advises against use of remdesivir for covid-19. Rodríguez-Tomàs et al. Antioxidants 2022, 11(6), 1184; https://doi.org/10.3390/antiox11061184, Published: 16 June 2022 11 Time reveals the truth! Now, after 2 years, we know that:  Several groups, including our own, have shown that whole-lung radiation at doses of 0.5–1.5 Gy can accelerate the recovery in clinical and radiographic status without acute toxicity [12,13,14,15,16,17,18,19,20,21].". LDRT for COVID-19

12. And viruses can evolve faster when there is selection pressure, he says, because mutations are more likely to stick around if they give the virus an increased ability to propagate under certain environmental conditions.

�ݺ�ߣ

Time reveals the truth.pdf

Recommended

More Related Content

Similar to Time reveals the truth.pdf (20)

More from SMJ Mortazavi (8)

Recently uploaded (20)

Time reveals the truth.pdf